Columbus、OHにおける卵巣がんの臨床試験
Columbusとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する39件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
被験者募集中第2/3相
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- 他13件
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
被験者募集中第1/2相
- Research Site, Columbus
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- The Mark H Zangmeister Center /ID# 275106, Columbus
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第2相
- Site 0243 - Mark H Zangmeister Cancer Center, Columbus
- Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard · 10マイル先
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
被験者募集中第1/2相
- The Ohio State University Wexner Medical Center, Columbus
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
被験者募集中第1/2相
- The Ohio State University Wexner Medical Center, Columbus
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
被験者募集中第2相
- Research Site, Columbus
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- The Mark H Zangmeister Center, Columbus
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Hilliard · 10マイル先
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
被験者募集中第2相
- Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard · 10マイル先
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- Ohio Health Research Institute, Columbus
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第2相
- The Mark H Zangmeister Cancer Center Ohio, Columbus
- The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard · 10マイル先
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
被験者募集中第2相
- The Ohio State University Comprehensive Cancer Center, Hilliard · 10マイル先
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
被験者募集中第1/2相
- Ohio State University, Columbus
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
被験者募集中第3相
- Zangmeister Cancer Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
被験者募集中第1相
- The Ohio State University (OSU) Wexner Medical Center, Columbus
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
被験者募集中第3相
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
被験者募集中第3相
- OhioHealth Research Institute, Columbus
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
被験者募集中第1相
- The Ohio State University, Columbus
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
被験者募集中第1相
- Ohio State University Wexner Medical Center, Columbus
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
被験者募集中早期第1相
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- The Ohio State University, Columbus
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
被験者募集中第3相
- Site 0108, Columbus
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- 他8件
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- 他8件
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
被験者募集中第2/3相
- Ohio State University Wexner Medical Center, Hilliard · 10マイル先
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第2相
- Ohio State University, Columbus
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Stefanie Spielman Comprehensive Breast Center, Columbus
Lead-212 PSV359 Therapy for Patients With Solid Tumors
被験者募集中第1/2相
- Ohio State University, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
被験者募集中第1相
- Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
被験者募集中第1/2相
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Stefanie Spielman Comprehensive Breast Center, Columbus
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
被験者募集中第2相
- The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
被験者募集中第1/2相
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Columbus
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
- Pittsburgh, PA30件の研究
Columbusにおける他の研究
- 非小細胞肺癌57件の研究
- 乳がん40件の研究
- がん（全種類）38件の研究
- 肺がん37件の研究
- 急性骨髄性白血病35件の研究
- 慢性リンパ性白血病28件の研究
- 転移性癌27件の研究
- 子宮内膜がん25件の研究
- 前立腺がん24件の研究
- 多発性骨髄腫24件の研究
- 大腸癌24件の研究
- 悪性黒色腫21件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。